Shyam Sathanandam

Prof. Shyam Sathanandam

University of Tennessee Health Science Center Memphis
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
SSShyam Sathanandam
Shyam Sathanandam
DGDan Gutfinger
Dan Gutfinger
LOLaura O'BRien
Laura O'BRien
TFThomas J. Forbes
Thomas J. Forbes
MGMatthew J. Gillespie
Matthew J. Gillespie
EZEvan M. Zahn
Evan M. Zahn
Objectives: Characterize the safety and effectiveness of the Amplatzer Piccolo Occluder for patent ductus arteriosus (PDA) closure.Background: The presence of a hemodynamically significant PDA has been associated with an increased risk of morbidity and mortality in children born premature.Methods: This was a single arm, prospective, multicenter, non‐randomized study to evaluate the Amplatzer Piccolo Occluder to treat PDA in patients ≥700 g. From June 2017 to February 2019, 200 patients were enrolled at nine centers, with 100 patients weighing ≤2 kg. Primary effectiveness endpoint was the rate of PDA closure at 6‐month follow‐up. Primary safety endpoint was the rate of major complications through 6 months. Secondary endpoint was rate of significant pulmonary or aortic obstruction through 6 months' follow‐up.Results: The implant success rate was 95.5% (191/200) overall and 99% in patients ≤2 kg (99/100). The primary effectiveness endpoint was achieved in 99.4% of implanted patients. Four patients experienced a primary safety endpoint event (2 transfusions, 1 hemolysis, and 1 aortic obstruction). There were no branch pulmonary artery obstructions. Five patients, all ≤2 kg, were noted to have worsening of tricuspid regurgitation (TR) after the procedure. None of the TR incidences manifested clinically. The Amplatzer Piccolo Occluder received FDA approval in January 2019 and became the first device approved for PDA closure in patients ≥700 g.Conclusions: This study supports the safety and effectiveness of the Amplatzer Piccolo Occluder, particularly in patients between 700 g and 2 kg where there is currently a significant unmet need in the United States. ClinicalTrials.gov identifier: NCT03055858.

30 September 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SSShyam Sathanandam
Shyam Sathanandam
KBKaitlin Balduf
Kaitlin Balduf
SCSandeep Chilakala
Sandeep Chilakala
KWKristen Washington
Kristen Washington
KAKimberly Allen
Kimberly Allen
RPRanjit Philip
Ranjit Philip

3 November 2015 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
RPRanjit Philip
Ranjit Philip
BWB. Rush Waller
B. Rush Waller
VAVijaykumar Agrawal
Vijaykumar Agrawal
DWDena Wright
Dena Wright
AAAlejandro Arevalo
Alejandro Arevalo
SSShyam Sathanandam
Shyam Sathanandam

30 June 2021 in Pediatric Cardiology
Verified
Journal Article
Open access
PDF file
SSShyam Sathanandam
Shyam Sathanandam
DGDan Gutfinger
Dan Gutfinger
BMBrian Morray
Brian Morray
DBDarren Berman
Darren Berman
MGMatthew Gillespie
Matthew Gillespie
EZEvan M. Zahn
Evan M. Zahn
Transcatheter closure of patent ductus arteriosus (PDA) in premature infants is a feasible, safe, and an effective alternative to surgical ligation and may be performed with an implant success rate of 97%. Major procedural complications related to transcatheter PDA closure in extremely low birth weight (ELBW) infants are relatively infrequent (< 3%) ,but may be associated with a fatality if not optimally managed. Operators performing transcatheter PDA closures should be knowledgeable about these potential complications and management options. Prompt recognition and treatment are often necessary to avoid serious consequences. With strict guidelines on operator training, proctoring requirements, and technical refinements, transcatheter PDA closure in ELBW infants can be performed safely with low complication rates. This article summarizes the consensus guidelines put forward by a panel of physicians for the prevention and management of periprocedural complications of transcatheter PDA closure with the Amplatzer Piccolo Occluder in ELBW infants.

26 November 2016 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SSShyam Sathanandam
Shyam Sathanandam
HJHenri Justino
Henri Justino
BWB. Rush Waller
B. Rush Waller
WRWolfgang Radtke
Wolfgang Radtke
AQAthar M. Qureshi
Athar M. Qureshi

11 February 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
SPSarah Parkerson
Sarah Parkerson
RPRanjit Philip
Ranjit Philip
ATAjay Talati
Ajay Talati
SSShyam Sathanandam
Shyam Sathanandam
The patent ductus arteriosus (PDA) is the most commonly found cardiac condition in neonates. While there have been several studies and thousands of publications on the topic, the decision to treat the PDA is still strongly debated among cardiologists, surgeons, and neonatologists. This is in part due to the shortage of long-term benefits with the interventions studied. Practice variations still exist within sub-specialties and centers. This article briefly summarizes the history, embryology and histology of the PDA. It also succinctly discusses the hemodynamic significance of a PDA which builds the framework to review all the available literature on PDA closure in premature infants, though not a paradigm shift just yet; it introduces transcatheter PDA closure (TCPC) as a possible armament to the clinician for this age-old problem.